These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 798198)

  • 41. [Clinical evaluation of a new drug (CH 13437) in the treatment of hyperlipemia].
    Arteaga A; Foradori A; Eyzaguirre J; Lira P; Vasquez A; Soto S; Alliende ME; Guzman L
    Rev Med Chil; 1970 Oct; 98(10):689-94. PubMed ID: 4927028
    [No Abstract]   [Full Text] [Related]  

  • 42. The effect of pirozadil on plasma lipids and lipoproteins in 1185 hyperlipidaemic subjects. Multicentre study in general practice in Spain.
    Tapounet R; Marti Ragué I
    Drugs Exp Clin Res; 1987; 13(7):447-50. PubMed ID: 3652931
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Multicenter clinical, double blind, and randomized study to assess the effectiveness and safety of binifibrate versus gemfibrozil in type IIa, IIb, and IV hyperlipidemia].
    Corominas Vilardell A; de Oya Otero M; Escobar Jiménez F; Anguera Vila A; Ariño Armengol B
    An Med Interna; 1993 Nov; 10(11):537-41. PubMed ID: 8117868
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Hyperlipemia and pancreatitis].
    Carrillo Penso N; Carrasquero O; Medina JA
    G E N; 1981; 35(1-2):15-27. PubMed ID: 6816659
    [No Abstract]   [Full Text] [Related]  

  • 45. [The effect of gemfibrocil on serum lipids and lipoproteins in patients with hyperlipoproteinemia].
    Weisweiler P; Neureuther G; Schwandt P
    Verh Dtsch Ges Inn Med; 1978; (84):1160-3. PubMed ID: 741916
    [No Abstract]   [Full Text] [Related]  

  • 46. [Clinical trial of tibric acid, a new hypolipidemic agent].
    Noseda G; Sirtori CR
    Schweiz Med Wochenschr; 1974 Dec; 104(51):1917-22. PubMed ID: 4438990
    [No Abstract]   [Full Text] [Related]  

  • 47. [Current trends in the therapy of arteriosclerotic disease].
    Toscano S
    G Clin Med; 1974 Jan; 55(1):27-39. PubMed ID: 4369524
    [No Abstract]   [Full Text] [Related]  

  • 48. [Therapy of hyperlipidemia. Clinical experience with clinofibrate].
    Avellone G; Di Garbo V; Strano A
    Clin Ter; 1989 Apr; 129(1):25-9. PubMed ID: 2525449
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Long-term effect of alufibrate in various types of hyperlipidaemia (author's transl)].
    Stähelin HB; Hartmann G
    Dtsch Med Wochenschr; 1974 Jun; 99(26):1392-4 passim. PubMed ID: 4601124
    [No Abstract]   [Full Text] [Related]  

  • 50. Gemfibrozil in hyperlipidaemia: an open, single blind trial.
    Varthakavi PK; Turakhia DP; Sharma SS; Salgaonkar DS; Nihalani KD; Joshi VR
    J Assoc Physicians India; 1990 Feb; 38(2):136-40. PubMed ID: 2380132
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hypolipidaemic effect of xantinol nicotinate: a clinical trial.
    Dhorranintra B; Khunawat P; Patalung BN; Prabhan C
    J Med Assoc Thai; 1983 May; 66(5):269-73. PubMed ID: 6348198
    [No Abstract]   [Full Text] [Related]  

  • 52. Hyperlipidemia: reducing the chances of cardiovascular disease.
    Nash DT
    Geriatrics; 1984 Jul; 39(7):99-100, 103-4,108-9 passim. PubMed ID: 6588017
    [No Abstract]   [Full Text] [Related]  

  • 53. Gemfibrozil: a new lipid lowering agent. Open forum.
    Proc R Soc Med; 1976; 69 Suppl 2(Suppl 2):115-20. PubMed ID: 1019151
    [No Abstract]   [Full Text] [Related]  

  • 54. [Hypolipemic effects of 1-10(hydroxy-2 ethylthio) decane (LL1558), based on 77 cases of essential hyperlipidemia].
    Rouffy J; Loeper J
    Therapie; 1972; 27(3):433-44. PubMed ID: 4570211
    [No Abstract]   [Full Text] [Related]  

  • 55. [The problem of an antilipemic synergism between the action of nicotinic acid and the sulphated polyanion SP54 (author's transl)].
    Levy H
    Med Klin; 1974 Sep; 69(36):1441-7. PubMed ID: 4280008
    [No Abstract]   [Full Text] [Related]  

  • 56. The effect of Gemfibrozil on human serum apolipoproteins and on serum reserve cholesterol binding capacity (SRCBC).
    Børresen AL; Berg K; Dahlén G; Gillnäs T; Ericson C
    Artery; 1981; 9(1):77-86. PubMed ID: 7018466
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Preliminary observations on the effect of gemfibrozil on the excretion of faecal bile acids.
    Baird IM; Lewis B; Hill JM
    Proc R Soc Med; 1976; 69 Suppl 2(Suppl 2):112-4. PubMed ID: 1019150
    [No Abstract]   [Full Text] [Related]  

  • 58. [The value of chemotherapeutic intervention on primary hyperlipidemias in the prevention of coronary arteriosclerosis].
    Forti N; Dereviacki BE; Giannini SD
    Arq Bras Cardiol; 1988 Jul; 51(1):49-53. PubMed ID: 3073736
    [No Abstract]   [Full Text] [Related]  

  • 59. [Treatment of primary hyperlipidemia with 5-methylpyrazinecarboxylic acid (acipimox)].
    Quintão EC; de Castilho LN
    Arq Bras Cardiol; 1985 Jan; 44(1):37-40. PubMed ID: 4062591
    [No Abstract]   [Full Text] [Related]  

  • 60. [Statistical analysis of variations in total cholesterol, HDL, HDL2, HDL3, LDL-cholesterol, VLDL-triglycerides, apo-A and apo-B lipoproteins in dyslipidemias during antilipemic therapy].
    Melloni GF; Scarazatti E; Garanzelli P; Melloni R
    Boll Soc Ital Biol Sper; 1985 Jan; 61(1):7-14. PubMed ID: 3884023
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.